Skip to main content

Table 3 Inter-treatment (combined vs deferiprone and combined vs deferoxamine) prospective comparisons in patients with basal global heart T2* < 20 ms

From: Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

  P Deferiprone group (n = 9) Combined group (n = 26) Deferoxamine group (n=21) P
Mean Diff Serum Ferritin (ng/ml) 0.005 −112 ± 241 −679 ± 835 −133 ± 575 0.017
Mean Diff Global Heart T2* (ms) 0.107 +8.8 ± 8.6 +4.5 ± 6.1 +3.7 ± 5.5 0.644
Mean Diff MRI CIC (mg/g dry w) 0.540 −0.36 ± 1.78 −0.75 ± 1.67 −0.35 ± 0.55 0.255
Mean Diff N seg. With T2* < 20 ms 0.100 −6.0 ± 5.6 −2.4 ± 3.8 −2.9 ± 3.7 0.638
Mean Diff Mid-Septum T2* (ms) 0.295 +6.1 ± 7.4 +3.3 ± 7.1 2.9 ± 5.6 0.841
Mean Diff LV EF (%) 0.181 +5.0 ± 6.4 +1.5 ± 6.7 +2.0 ± 6.5 0.802
Mean DIFF LV EDVI (ml/m2) 0.796 −6.0 ± 12.3 −4.6 ± 13.9 −7.7 ± 11.6 0.432
Mean Diff RV EF (%) 0.137 +6.8 ± 3.7 +3.2 ± 6.7 +0.2 ± 8.8 0.187
Mean Diff RV EDVI (ml/m2) 0.909 −6.9 ± 11.7 −7.5 ± 12.5 −5.8 ± 17.1 0.702
Mean Diff Liver T2* (ms) 0.010 +2.0 ± 7.5 +5.7 ± 6.9 +2.9 ± 4.2 0.026
Mean Diff MRI LIC (mg/g/dw) 0.009 −0.1 ± 3.2 −4.9 ± 6.1 −1.7 ± 2.8 0.024